dilution

New shares, convertibles or warrants that could reduce existing shareholders' ownership.

Exposure · 11 companies

Show
8-K events
Match any selected event
8-K event types
More events

Only filters 8-Ks. Other selected forms stay visible.

  • ADC AGREE REALTY CORP

    Exposed“Forward-sale obligations are expected to settle between June 2026 and May 2027 and can be settled physically, in cash, or in net shares, creating flexibility as well as potential dilution or cash needs.”

    Latest 10-QQ3 FY2026Positive ·

    Retail acquisitions lift rents, but share issuance tempers per-share growth and September’s notes carry a higher borrowing cost.

    • Revenue$213.9MYoY +16.7%
    • Net income$68.4MYoY +31.2%
  • APMD Apnimed, Inc.

    Exposed“Further equity issuance, awards, warrants, or financing could dilute holders and pressure the share price.”

    Latest 424B4final IPO prospectusBankruptcy / going concernAccounting issueCEO/CFO change ·

    Develops Oxnimbi, a once-nightly sleep apnea pill; $192M all-primary raise funds regulatory work and launch if approved.

  • ARCC ARES CAPITAL CORP

    Exposed“The transaction would dilute existing ARCC stockholders’ ownership and voting power through the issuance of shares to MFIC stockholders.”

    Latest 10-QQ3 FY2026 ·

    MFIC acquisition would expand the portfolio as lower lending yields pressure income and investment markdowns erode NAV.

    • Total investment income$763.0MYoY −2.4%
    • Net income$319.0MYoY −21.0%
  • ARMP Armata Pharmaceuticals, Inc.

    Exposed“Equity and convertible financing may dilute shareholders or give other investors preferences, while debt may restrict operations.”

    Latest 10-QQ3 FY2026NegativeBankruptcy / going concern ·

    AP-SA02 advances toward Phase 3 with FDA support and expanded MTEC funding, but a cash shortfall threatens development.

    • Revenue$3.2MYoY +173.6%
    • Net income$54.9Mvs −$26.7M year ago
  • CAPR CAPRICOR THERAPEUTICS, INC.

    Exposed“Further financing may involve equity dilution, debt covenants, or partnership terms that require relinquishing rights.”

    Latest 10-QQ3 FY2026NegativeRestructuring ·

    Deramiocel’s FDA bid narrows to upper-limb impairment after an adverse cardiac efficacy vote; a Nippon Shinyaku dispute complicates launch plans.

    • Revenue$0vs $0 year ago
    • Net income−$42.7MYoY −73.6%
  • GME GameStop Corp.

    Exposed“Additional share issuance, including a potential at-the-market program, could dilute holders.”

    Latest 8-KListing notice ·

    Warrants stop NYSE trading before the Oct. 30, 2026 open and expire worthless unless exercised for $32 cash per share by 5 p.m. ET that day.

  • INTC Intel

    Exposed“The offering is equity financing and may dilute shareholders; the share-count effect is not specified here.”

    Latest 10-QQ3 FY2026Impairment / charge ·

    Hyperscaler demand for premium server chips offsets client weakness; Kiryat Gat fab accident adds Q4 costs.

    • Revenue$16.5BYoY +20.9%
    • Net income$3.3BYoY −18.3%
  • MRNA Moderna

    Exposed“Conversion settled partly or wholly in shares could dilute existing shareholders and pressure the share price.”

    Latest 8-KPositiveDebt financing ·

    Credit amendment cuts initial and delayed-draw term-loan margins 75 bp and extends maturity to November 2031.

  • NOW ServiceNow

    Exposed“The awards represent potential future equity dilution; the filing provides target values, not share counts or recognized compensation expense.”

    Latest 10-QQ3 FY2026Restructuring ·

    Armis and Veza acquisitions expand the security platform as deal amortization and infrastructure spending squeeze margins.

    • Revenue$4.1BYoY +20.5%
    • Net income$277.0MYoY −44.8%
  • SMCI Supermicro

    Exposed“Conversion of the notes or Mandatory Convertible Preferred Stock, and payment of preferred dividends in common shares, could dilute shareholders.”

    Latest 10-QQ1 FY2027MixedAccounting issue ·

    GB200 and GB300 shipments accelerated and richer mix lifted margins; inventory and receivables kept operating cash flow negative.

    • Revenue$19.9Bvs $5.0B year ago
    • Net income$1.6Bvs $168.3M year ago
  • SNSC SunScout Holding Ltd

    Exposed“CRHL’s enforcement or conversion rights under a convertible loan could substantially dilute ownership and reduce control of SunScout New Zealand and SunScout Limited.”

    Latest 424B4final IPO prospectusMixedControlled company ·

    Solar-project developer commercializing solar-powered autonomous mowers; Cywinski founders retain 96.55% of post-IPO voting power.

Feedback